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Background: Multidrug resistance is the main obstacle to the efficiency of systemic chemo-
therapy against hematologic malignancy. This study investigated the reversible effect of the 
copolymer wogonin and daunorubicin coloaded into Fe3O4 magnetic nanoparticles, and the 
mechanism potentially involved.
Methods: The growth inhibition rate of K562/A02 cells was investigated by MTT assay, and 
apoptosis of cells and the intracellular daunorubicin concentration were detected by flow cytom-
etry. Distribution of nanoparticles taken up by K562/A02 cells was observed under a transmis-
sion electron microscope and demonstrated by Prussian blue staining. The transcription level 
of MDR1 mRNA and expression of P-glycoprotein were determined by reverse transcriptase 
polymerase chain reaction and Western blotting assay, respectively.
Results: The reversible effect of daunorubicin-wogonin magnetic nanoparticles was 8.87-fold 
that of daunorubicin + wogonin and of daunorubicin magnetic nanoparticles. Transmission 
electron microscopy and Prussian blue staining revealed that the nanoparticles were located in 
the endosome vesicles of cytoplasm. Also, the apoptosis rate and accumulation of intracellular 
daunorubicin in the daunorubicin-wogonin magnetic nanoparticle group were significantly higher 
than that in the daunorubicin, daunorubicin + wogonin, and daunorubicin magnetic nanoparticle 
groups. Furthermore, transcription of MDR1 mRNA and expression of P-glycoprotein in K562/
A02 cells were significantly downregulated in the daunorubicin-wogonin magnetic nanoparticle 
group compared with the other groups.
Conclusion: These findings suggest that the remarkable effects of the novel daunorubicin-
wogonin magnetic nanoparticle formulation on multidrug resistant K562/A02 leukemia cells 
would be a promising strategy for overcoming multidrug resistance.
Keywords: magnetic nanoparticles, Fe3O4, wogonin, multidrug resistance, daunorubicin, 
P-glycoprotein
Introduction
Multidrug resistance is the major obstacle to the efficiency of chemotherapy in the 
treatment of leukemia.1 The mechanisms associated with multidrug resistance in cancer 
have been widely explored, and chemotherapy-induced upregulation of P-glycoprotein 
is considered the major event in establishing multidrug resistance in cancer cells.2 Much 
research attention has been focused on the discovery and development of agents that 
can inhibit P-glycoprotein with high efficiency and low toxicity.3–5 However, these 
compounds, with their low efficiency and/or high toxicity, are often nonspecific.6,7 The 
first and second generations of P-glycoprotein inhibitors have now been tested in clinic 
trials, but their therapeutic effects and safety profiles have not been ideal.6,7 Successful 
management of cancers with overexpressed P-glycoprotein would be greatly aided 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2843
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S32065International Journal of Nanomedicine 2012:7
by novel agents with high efficiency and/or low toxicity. 
Wogonin (5,7-dihydroxy-8-methoxy flavone) is a flavone 
originating from the roots of Scutellaria baicalensis Georgi. 
One study has shown that wogonin 10–30 µmol/L acted as 
an inhibitor of P-glycoprotein and consequently increased 
the cellular content of chemotherapeutic agents in multidrug 
resistant cancer cells.8 On the other hand, wogonin can inhibit 
apoptosis induced by chemotherapeutic agents in normal cells, 
such as thymocytes.9
However, sequential or concurrent administration of a 
chemosensitizer and a cytotoxic drug or a combination of 
drugs cannot guarantee the co-action of intended drugs in the 
same cancer cells because of their different pharmacokinetics 
and tissue disposition. It is exciting that magnetic nanopar-
ticles, with their biodegradable nature, biocompatibility, and 
low toxicity, possess the capability to encapsulate a single 
drug or multiple drugs with a variety of properties, ranging 
from highly water-soluble to poorly water-soluble.10–13 In 
addition, its passive targeting properties may reduce side 
effects during chemotherapy,14 rendering it a promising drug 
delivery system.
Therefore, in this study, to overcome the dose-limiting 
side effects of conventional chemotherapeutic agents, as 
well as to reduce the risk of therapeutic failure as a result of 
multidrug resistance, we undertook a rational design of bio-
compatible magnetic nanoparticles for sustained delivery of 
wogonin and daunorubicin and also investigated the potential 
mechanisms involved.
Materials and methods
Chemicals
Daunorubicin hydrochloride (Huifengda Chemical Co, 
Jinan, China), wogonin (Key Laboratory of Carcinogenesis 
and Intervention, Jiangsu Province, China   Pharmaceutical 
University, China), RPMI 1640 medium (Gibco/BRL, 
Gaithersburg, MD), newborn bovine serum (Sijiqing, 
Hangzhou, China), adriamycin (Hisun Phamaceutical Co, 
Zhejiang, China),TRIzol® (Invitrogen, Carlsbad, CA) were 
used. A reverse transcriptase polymerase chain reaction (RT-
PCR) kit was purchased from Takara Biotechnology (Dalian, 
China). Monoclonal antibodies of P-glycoprotein and β-actin 
were from Santa Cruz Biotechnology (Santa Cruz, CA). All 
other chemicals were of analytic grade.
Preparation of drug-loaded Fe3O4 
magnetic nanoparticles
Wogonin was dissolved in absolute dimethyl sulfoxide 
to give a 1 mol/L solution, and the final concentration of 
dimethyl sulfoxide in the medium of wogonin-treated cells 
was less than 0.05% (v/v), showing no toxicity in K562/
A02 cells.15 Magnetic nanoparticles were produced using 
the electrochemical deposition method13 for use in the pres-
ent experiment in order to obtain a colloidal suspension of 
magnetic nanoparticles.
In total, 10 µmol of magnetic nanoparticles were well 
distributed by ultrasound in 10 mL of RPMI 1640 medium 
containing 10% (v/v) inactivated newborn bovine serum.16 
Daunorubicin was dissolved in RPMI 1640 medium con-
taining 10% (v/v) inactivated newborn bovine serum to 
obtain a 1 mmol/L solution. Various concentrations of 
daunorubicin and wogonin 20 µmol/L were added into the 
aqueous dispersion of magnetic nanoparticles at a molar 
ratio of 1/2/4/8/16/32/64:20:100. The mixture was kept 
below 4°C for 48 hours to enable the drugs to conjugate 
with the magnetic nanoparticles by mechanical absorption 
polymerization.10,13
Cell culture
K562, a human chronic myeloid leukemia blast crisis cell 
line, and K562/A02, a K562 cell line resistant to adriamycin, 
were cultured in RPMI 1640 medium supplemented with 10% 
newborn bovine serum, 100 U/mL penicillin, and 100 µg/mL 
streptomycin at 37°C in a humidified atmosphere containing 
5% CO2, and passaged every two days. The resistant cell line 
was incubated in the presence of adriamycin 1 µg/mL until 
at least 3 days before starting the experiments.
Cytotoxicity assay
In vitro cytotoxicity was measured using the MTT assay. 
K562/A02 cells were seeded in 96-well plates at a density 
of 2 × 103 cells/well per 0.1 mL of medium, and incubated 
with daunorubicin 1–64 µmol/L, Fe3O4 magnetic nanopar-
ticles 0.1–0.5 (v/v), wogonin 10–50 µmol/L, daunorubicin 
1–64 µmol/L + wogonin 20 µmol/L, daunorubicin magnetic 
nanoparticles at a molar ratio of 1/2/4/8/16/32/64:100, or 
daunorubicin-wogonin magnetic nanoparticles at a molar 
ratio of 1/2/4/8/16/32/64:20:100 at 37°C for 24, 48, and 
72 hours. Meanwhile, RPMI 1640 medium was used as the 
blank control. After incubation, 20 µL of MTT 0.5 mg/mL 
were added to each well and cultured for 4 hours at 37°C. 
Thereafter, 150 µL of dimethyl sulfoxide were added to each 
well to dissolve the formazan crystals using an automated 
shaker to stir the cells slightly. Absorbance of the suspen-
sion was measured by optical density (OD) at a wave length 
of 490 nm. The cell inhibition ratio (%) was calculated as 
(1 − OD treated group/OD control group) × 100. The IC50 
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was defined as the concentration required for 50% inhibition 
of cell growth.
Qualitative and quantitative evaluation  
of Fe3O4 magnetic nanoparticle uptake  
in cells
Transmission electron microscopy
K562/A02 cell suspensions were seeded at a density of 
5 × 105 cells/well in 6-well plates and incubated with 10% 
(v/v) magnetic nanoparticles for 48 hours at 37°C. After 
incubation, the cells were collected and fixed for 4 hours at 
4°C in 2.5% glutaraldehyde, and fully washed in 0.1 mol/L 
phosphate-buffered saline three times. The cells were then 
post-fixed at 4°C in 2% osmium tetroxide for 2 hours, and 
dehydrated in a graded series of ethanols and embedded in 
epoxy resin. Thereafter, the embedded cells were cut into 
ultrathin sections (75 nm) and stained with uranyl acetate and 
lead citrate. Finally, the sections were viewed by transmission 
electron microscopy (JEM-2100, JEOL, Tokyo, Japan).
Optical microscopy
After incubating with 0.1 (v/v) magnetic nanoparticles for 
48 hours at 37°C, the cells were harvested and made into cell 
smears. Before observation by optical microscopy, the cells 
were stained with Prussian blue. The cells on the slide were 
continuously incubated for 30 minutes in 2% potassium fer-
rocyanide and 6% hydrochloric acid, and then counterstained 
with nuclear fast red for 3 minutes. The smears were viewed 
under an optical microscope (B × 41M, Olympus, Tokyo, 
Japan) at 1000 × amplification.
Apoptosis assay by flow cytometry
After incubation with different drugs, the cells were collected 
at 48 hours, washed twice with phosphate-buffered saline, and 
suspended in 200 µL of binding buffer and 10 µL of Annexin 
V-FITC for 20 minutes in the dark. Analyses were done 
using a FACSCalibur® flow cytometer (Becton   Dickinson, 
San Antonio, TX) with Cell Quest™ software.
Cellular accumulation of daunorubicin
Cellular accumulation of daunorubicin was analyzed by flow 
cytometry. In brief, after incubation with different drugs for 
48 hours, the cells were collected and washed with 0.1 mol/L 
phosphate-buffered saline three times. Thereafter, 500 µL of 
phosphate-buffered saline was added to each sample to resus-
pend the cells. The cellular accumulation of daunorubicin in 
each sample was determined using the flow cytometer at a 
wave length of 488 nm.
RT-PCR assay
The RT-PCR method was used to evaluate the qualitative 
efficacy of MDR1 with drugs as previously described at the 
transcription level. After incubation, the cells were lysed 
and total RNA was extracted with TRIzol. 4 µg of total 
RNA was added to reverse transcriptase buffer, 25 mmol/L 
of MgCl2, 10 mmol/L deoxyribonucleotide triphosphates, 
random 9 mers (50 pmol/µL), RNase inhibitor (40 U/µL), 
and avian myeloblastosis virus reverse transcriptase (5 U/µL) 
to provide a final total volume of 25 µL. To obtain cDNA, 
the conditions of reverse transcriptase were 42°C for one 
hour, 85°C for 5 minutes, and then 5°C for 5 minutes. 
The designed PCR primers included MDR1 primer (sense 
primer 5′-  AACGGAAGCCAGAACATTCC-3′, antisense primer 
5′-AGGCTTCCTGTGGCAAAGAG-3′) and β-actin primer 
(sense primer 5′-GCTCGTCGT CGACAACG GCTC-3′, anti-
sense primer 5′-CAAACATGATCTGGGT CATCTTCTC-3′). 
The amplified PCR products were 353 base pairs for β-actin 
and 180 base pairs for MDR1. The newly   synthesized cDNA 
was amplified by PCR, each cycle comprising denaturation 
at 95°C for 40 seconds, annealing at 52°C for 30 seconds, 
and elongation at 72°C for 35 seconds.   Predenaturing was 
performed at 95°C for 2 minutes and final extension at 72°C 
for 10 minutes. RT-PCR products were   analyzed by ScnImage 
software (Scion   Corporation, Frederick, MD) with ethidium 
bromide-stained 1.5% agarose gels.
Western blotting assay
After treatment as before, total protein was isolated on ice and 
subjected to 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis using a modified radioimmunoprecipitation 
assay buffer, and then transferred to a polyvinylidene difluoride 
membrane (65421, Pall Corporation, Port Washington, NY). 
Nonspecific binding sites were blocked with 5% nonfat milk 
for one hour at room temperature. The blots were stained with 
mouse monoclonal antihuman P-glycoprotein (1:200) or β-actin 
(1:400) antibodies overnight at 4°C, and then followed by 
horseradish peroxidase-labeled rabbit-mouse immunoglobulin 
G (1:5000) as a secondary antibody. The blots were visualized 
by enhanced chemiluminescence (ECL system, Amersham, 
UK), and β-actin was used as the internal control.
Statistical analysis
All data were expressed as the mean ± standard deviation, 
and analyzed using SPSS software (version 18.0, SPSS Inc, 
Chicago, IL). Differences between the groups were evaluated 
using one-way analysis of variance. A value of P , 0.05 was 
considered to be statistically significant.
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Results
Nanoparticles located in the endosome vesicles of the 
cytoplasm were observed by transmission electron 
microscopy, and nearly 100% of the cells were labeled 
with Prussian blue stain after incubation for 48 hours. 
The diameter of a single blank magnetic nanoparticle was 
16.72 ± 1.37 nm.
Cell survival
As the results of the MTT assay show, daunorubicin, a 
combination of daunorubicin + wogonin, daunorubi-
cin magnetic nanoparticles, and daunorubicin-wogonin 
magnetic nanoparticles showed antiproliferative activity 
against drug-resistant cells in a dose and time-dependent 
manner (Figure 2D–F). Meanwhile, 0.1–0.4 (v/v) magnetic 
nanoparticles alone and 0–40 µmol/L wogonin alone did not 
have a significant influence on cell proliferation (survival 
faction . 90%,10 Figure 2A and B), and neither 20 µmol/L 
wogonin nor 0.1 (v:v) magnetic nanoparticles induced sig-
nificant cell inhibition at 24, 48, and 72 hours (Figure 2C). 
After incubation for 48 hours, the reversible effect of 
daunorubicin-wogonin magnetic nanoparticles (IC50 daunorubicin/
IC50 daunorubicin-wogonin magnetic nanoparticles) was 8.87-fold, which was 
higher than that of daunorubicin + wogonin (IC50 daunorubicin/ 
IC50 daunorubicin + wogonin, 4.85-fold) and daunorubicin-magnetic 
nanoparticles (IC50 daunorubicin/IC50 daunorubicin-magnetic nanoparticles, 3.9-fold). 
The difference was statistically significant (P , 0.05).
Apoptosis assay by flow cytometry
After incubation for 48 hours, the apoptotic rates of K562/
A02 cells treated with the control, daunorubicin, magnetic 
nanoparticles, wogonin, daunorubicin + wogonin, dauno-
rubicin magnetic nanoparticles, and daunorubicin-wogonin 
magnetic nanoparticles were 7.80% ± 0.36%, 9.08% ± 0.33%, 
8.23% ± 0.47%, 8.71% ± 0.54%, 33.65% ± 1.96%, 
28.47% ± 2.28%, and 41.04% ± 2.63%, respectively. 
  Compared with the control group, apoptotic rates in the 
  daunorubicin + wogonin, daunorubicin magnetic nanoparticle, 
and daunorubicin-wogonin magnetic nanoparticle groups were 
significantly increased (P , 0.05). Although the   combination 
of daunorubicin + wogonin induced significant apoptosis, 
  daunorubicin-wogonin magnetic nanoparticles showed much 
higher induction of apoptosis (P , 0.05, Figure 3).
Cellular accumulation of daunorubicin
The relative fluorescence intensity (fluorescence intensity-
treated group/fluorescence intensity control group) was 
3.74 ± 0.34 for K562/A02 cells incubated with 2 µmol/L of 
daunorubicin for 48 hours, 14.71 ± 0.84 for daunorubicin + 
wogonin, 12.71 ± 0.65 for daunorubicin magnetic nanopar-
ticles, and 24.31 ± 2.82 for daunorubicin-wogonin magnetic 
nanoparticles. The daunorubicin + wogonin, daunorubicin 
magnetic nanoparticle, and daunorubicin-wogonin magnetic 
nanoparticle groups showed higher daunorubicin accumu-
lation than did the daunorubicin alone group (P , 0.05). 
Notably, daunorubicin-wogonin magnetic nanoparticles led 
to an increase in intracellular daunorubicin concentration 
compared with the daunorubicin + wogonin and daunorubicin 
magnetic nanoparticle groups (P , 0.05).
Expression of MDR1/P-glycoprotein  
in K562/A02 cells
MDR1 mRNA was not detected in drug-sensitive K562 cells 
(data not shown), and was overexpressed in drug-resistant 
K562/A02 cell lines. Both daunorubicin and wogonin 
groups can downregulate transcription of MDR1 mRNA to 
some extent, and both were strengthened by the   addition of 
magnetic nanoparticles. Compared with the control group, 
MDR1 mRNA transcriptions were significantly inhib-
ited by nearly 44.85% ± 3.89% in the wogonin group, by 
59.13% ± 3.48% in the daunorubicin + wogonin group, and 
by 75.80% ± 4.32% in the daunorubicin-wogonin magnetic 
nanoparticle group (P , 0.05, Figure 5). The expression of 
Figure 1 Distribution of nanoparticles in K562/A02 cells incubated with and without 
10% (v/v) magnetic nanoparticles for 48 hours.
Notes: (A) Transmission electron micrograph for control, (B) transmission electron 
micrograph for 10% (v/v) magnetic nanoparticles, red arrows direct nanoparticles 
in the endosome vesicles, and the upper left and upper right pictures were the 
magnifications (10×), (C) Prussian blue staining for control, and (D) Prussian blue 
staining for 10% (v/v) magnetic nanoparticles.
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P-glycoprotein were significantly downregulated by nearly 
40.62% ± 2.57% in the wogonin group, by 69.93% ± 4.63% in 
the daunorubicin + wogonin group, and by 79.51% ± 4.48% 
in the daunorubicin-wogonin magnetic nanoparticle group, 
respectively, when compared with the control group 
(P , 0.05, Figure 6).
Discussion
A novel copolymer containing a nanoparticle, chemothera-
peutic agent, and chemosensitizer with high efficiency and 
high potency has been devised in this work. Although there 
have been reports of sequential or concurrent administration 
of cytotoxic drugs and P-glycoprotein inhibitors, none could 
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Figure 2 (A) Viability of K562/A02 cells treated with different concentrations of magnetic nanoparticles, (B) viability of K562/A02 cells treated with different concentrations 
of wogonin, (C) surviving fraction of K562/A02 cells treated with 20 µmol/L wogonin or 0.1 (v/v) magnetic nanoparticles for 24, 48, and 72 hours, (D) inhibition rates of K562/
A02 cells treated with different concentrations of daunorubicin with and without magnetic nanoparticles for 48 hours, (E) inhibition rates of K562/A02 cells treated with 
coadministered daunorubicin + wogonin with and without magnetic nanoparticles for 48 hours, (F) IC50 of daunorubicin treated with daunorubicin, daunorubicin + wogonin, 
daunorubicin magnetic nanoparticles, and daunorubicin-wogonin magnetic nanoparticles for 24, 48, and 72 hours.
Abbreviations: DNR, daunorubicin; Wog, wogonin; MNPs, magnetic nanoparticles; IC50, inhibitory concentration at 50%.
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guarantee that the two drugs will have activity in the same 
cancer cells due to their different pharmacokinetics and 
tissue disposition. Since over expression of P-glycoprotein 
is the main cause of multidrug resistance in leukemia sys-
temic chemotherapy,2 we choose this combination.
Daunorubicin is an anthracycline and a substrate for 
P-glycoprotein,17 and the current standard of care for induc-
tion chemotherapy of acute myeloid leukemia includes 
3 days of daunorubicin.18 Although intensification of the 
dose of daunorubicin (90 mg/m2) improves the complete 
remission rate in acute myeloid leukemia,19,20 it will result 
in hematologic toxicity or adverse events.18 A low dose 
exposes some populations of tumor cells to sublethal doses 
of the chemotherapeutic agent used, resulting in onset of 
the multidrug-resistant phenotype.21 If one agent having 
the same or higher cytotoxicity can lower the dose of drug 
we utilize nowadays, it might be a promising solution for 
multidrug resistance. The copolymer in our research can 
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Figure 3 Apoptotic rates of K562/A02 cells incubated for 48 hours by flow cytometry. (A) control, (B) 2 µmol/L daunorubicin, (C) 0.1 (v/v) magnetic nanoparticles,   
(D) 20 µmol/L wogonin, (E) combination of 2 µmol/L daunorubicin and 20 µmol/L wogonin, (F) 2µmol/L daunorubicin magnetic nanoparticles (at a molar ratio of 2:100),   
(G) 2 µmol/L daunorubicin-wogonin magnetic nanoparticles (at a molar ratio of 2:20:100).
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lower the dose of daunorubicin used by 8.87-fold and 
owned higher fluorescence of daunorubicin compared 
with daunorubicin used alone. Even daunorubicin loaded 
with magnetic nanoparticles can lower the dose of dauno-
rubicin needed by 3.9-fold, its reversal power was signifi-
cantly lower than that of daunorubicin-wogonin magnetic 
nanoparticles.
Wogonin, a flavone originating from the root of a   Chinese 
herb, Scutellaria baicalensis Georgi, can impair the func-
tion of P-glycoprotein and increase the cellular content 
of the chemotherapeutic agent entering multidrug-resistant 
cells.8 In addition, the inhibitory potency of wogonin was 
nearly equal to that of the first-generation P-glycoprotein 
inhibitor,3 verapamil.8 We had taken the lead to investigate 
the influence of wogonin, and the results show that it did 
downregulate transcription of MDR1 mRNA and expres-
sion of P-glycoprotein in K562/A02 cells. Because this 
flavone does not generate significant cytotoxicity, increase 
apoptosis in multidrug-resistant cancer cells, or decrease 
induction of apoptosis in normal cells,9 wogonin could be 
an ideal P-glycoprotein inhibitor with high efficiency and 
low toxicity.
Magnetic nanoparticles, a promising biocompatible mate-
rial, have the features of satisfactory water solubilization, 
biocompatibility, and easy functionalization.10 A previous 
study in our laboratory showed that magnetic nanoparticles 
could improve the sensitivity of anticancer drugs and increase 
their effectiveness.12,13 We also found that magnetic nano-
particles have the capability to load single or multiple drugs 
with a variety of properties.11,12 The hydrodynamic diameter 
of ideal nanoparticles ranges from 10 nm to 100 nm, as 
  reported.22 If the diameter is less than 10 nm, most of them will 
undergo extravasation in tissue and be cleared by the kidney.23 
  However, if the diameter exceeds 100 nm, the nanoparticles 
will soon be eliminated from the circulation by the reticuloen-
dothelial system.23 In the present study, the mean size of the 
blank magnetic nanoparticles was 16.72 ± 1.37 nm, indicating 
that citric acid-functionalized magnetic nanoparticles were 
suitable for biological application and drug delivery. When 
the concentration of magnetic nanoparticles was 0.1 (v/v), 
they showed no obvious toxicity (Figure 2C) or apoptosis 
(Figure 3) to K562/A02 cells. Transmission electron micros-
copy suggested that the magnetic nanoparticles are taken up 
by the cell via membrane-bound vesicles, and shuttled to the 
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of 2 µmol/L daunorubicin combined with 20 µmol/L Wog, (D) 2 µmol/L daunorubicin magnetic nanoparticles (at a molar ratio of 2:100), (E) 2 µmol/L daunorubicin-Wog 
magnetic nanoparticles (at a molar ratio of 2:20:100), (F) relative fluorescence intensity of daunorubicin in treated cells.
Abbreviations: DNR, daunorubicin; Wog, wogonin; MNPs, magnetic nanoparticles; RFI, relative fluorescence intensity.
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Figure 6 Expression of P-glycoprotein after treatment for 48 hours.
Abbreviations: DNR, daunorubicin; MNPs, magnetic nanoparticles; Wog, wogonin.
cytosol in K562/A02 cells. The magnetic nanoparticles were 
stained using potassium ferrocyanide (blue), while the cells 
were stained using nuclear fast red. There were no blue gran-
ules in the controls; on the contrary, nearly 100% of multidrug 
resistant cells were labeled. Thus, the ability to overcome 
efflux pumps in the cell membrane and transport an active 
drug into the cell might be one of the proposed mechanisms 
that allows magnetic nanoparticles to be a potential strategy 
to overcome multidrug resistance.
Although inhibitors of P-glycoprotein have been devel-
oped as a way to overcome multidrug resistance, rapid 
drug metabolism may be one of the factors influencing the 
effect of treatment.24 It should be noticed that there were 
no significant differences in IC50 of daunorubicin between 
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the daunorubicin + wogonin and daunorubicin-wogonin 
magnetic nanoparticle groups at 24 hours, but this situation 
changed at 48 hours and 72 hours, when the IC50 of dauno-
rubicin in the daunorubicin-wogonin magnetic nanoparticle 
group was obviously lower than that in the daunorubicin + 
wogonin group. Possible reasons for this phenomenon might 
be that a large proportion of wogonin in the daunorubicin + 
wogonin group may have been metabolized to a residue 
which could inhibit P-glycoprotein further, and there is 
some evidence in the literature to support this,25 and the 
sustained-release properties of daunorubicin-wogonin 
magnetic nanoparticles might enable continuous release of 
the chemosensitizing agent, instead of rapid metabolism, 
and much more daunorubicin was released continuously 
from the copolymer after 24 hours. Also, a previous study 
in our laboratory showed that drug-loaded magnetic nano-
particles were able to release daunorubicin in a sustained 
manner for 25 days, and less than 20% of daunorubicin 
was released from the magnetic nanoparticles in 24 hours.11 
This sustained release might lead to an effective dose 
between two cycles of chemotherapy with maximal killing 
of malignant cells.
A copolymer with the power to reverse multidrug resis-
tance might enable particles to be taken up by membrane-
bound vesicles into cells such that their cargo becomes distal 
to the cell membrane and is inaccessible to the effects of 
ABC transporter-mediated drug efflux (Figure 1), raise the 
daunorubicin level in multidrug-resistant cells by releasing 
the copolymer from the vesicles (Figure 4), and downregulate 
expression of P-glycoprotein (Figure 6) at the same time. We 
believe that downregulation of P-glycoprotein and passive 
targeting of nanoparticles raise the intracellular concentration 
of daunorubicin, and the copolymer of daunorubicin-wogonin 
magnetic nanoparticles can induce the cell apoptosis rate to 
a higher degree as a result. We did not investigate sequen-
tial or concurrent administration of separate P-glycoprotein 
inhibitors and anticancer drug-loaded nanoparticles, but there 
have been reports demonstrating chemosensitizer coloading 
with an anticancer drug in the same nanoparticle resulting 
in higher drug uptake than found with coadministration of 
nanoparticles loaded with a single agent.26,27
Conclusion
These results indicate that the unique properties of 
daunorubicin-wogonin magnetic nanoparticles can reverse 
multidrug resistance in K562/A02 cells, which would be 
a promising strategy for overcoming multidrug resistance 
in the future.
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